Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Lineage Cell Therapeutics, Inc.

< Previous 1 2 3 4 Next >
Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at 2023 AAPS National Biotechnology Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.